HCC827 / HCC827-luc Orthotopic Mouse Model Service for Lung Cancer

The HCC827 / HCC827-luc orthotopic mouse model of lung cancer hosts the field’s reference EGFR exon 19-mutant human adenocarcinoma inside the thoracic cavity, where oncogene-addicted tumor growth, local invasion, and treatment response can be followed non-invasively and quantitatively by luciferase bioluminescence. Alfa Cytology runs this model as an integrated preclinical service — from authenticated CRL-2868 banking and HCC827-luc line qualification through intrathoracic implantation in nude recipients, scheduled whole-body imaging, erlotinib-class reference dosing, and endpoint analysis spanning thoracic tumor metrics, dissemination scoring, and histopathology.

Overview of HCC827 / HCC827-luc Orthotopic Mouse Model for Lung Cancer

HCC827 is a human non-small cell lung adenocarcinoma cell line deposited with ATCC as CRL-2868, isolated in 1994 by Adi Gazdar and John Minna from the lung of a 39-year-old female patient whose tumor showed bronchioloalveolar carcinoma features. Its defining alteration is an acquired deletion in exon 19 of EGFR (E746-A750), a sensitizing mutation that locks the receptor in a constitutively active state and renders the line exquisitely dependent on EGFR signaling — the reason HCC827 serves as the positive-control model in virtually every EGFR-tyrosine kinase inhibitor program, responding to first-generation agents such as erlotinib and gefitinib with frank tumor regression in vivo. The line is also notable for high PD-L1 expression, which has made it a substrate for PBMC-humanized checkpoint-inhibitor studies, and for its well-mapped resistance biology: prolonged drug exposure selects variants such as HCC827-ER1 and HCC827-GR1 that retain the exon 19 deletion but amplify c-MET and upregulate AXL, recapitulating the bypass-track resistance seen in patients without the T790M gatekeeper mutation.

Fig 1. Bioinformatics and western blot analysis showing that HER2, CXCL13 and CCL20 are expressed in LUAD tumors and cell lines including HCC827, providing the antigen and chemokine-ligand rationale for targeting HER2-positive HCC827 with CXCR5/CCR6-co-expressing CAR T cells in the orthotopic model. (Hu, Xiaoyuan, et al., 2025)

Orthotopically, HCC827-luc cells — created by stable luciferase transfection, for example via pMSCV-luc constructs with puromycin selection — are delivered intrathoracically into nude mice, where they establish locally invasive thoracic tumors that grow with the mechanics, vascular supply, and lymphatic drainage of the genuine lung site. Serial bioluminescence imaging after D-luciferin administration tracks thoracic burden from first engraftment through treatment and relapse, giving time-resolved pharmacodynamic readouts that caliper measurements on flank tumors simply cannot provide. This combination — a clinically canonical EGFR mutation, a drug-response profile validated across thousands of publications, a resistance-evolution system that mirrors clinical bypass signaling, and quantitative whole-animal imaging — makes the HCC827-luc orthotopic model a first-choice platform for benchmarking next-generation TKIs, rational combination regimens, and resistance-overcoming strategies in EGFR-mutant NSCLC.

Cell Line Information: HCC827 / HCC827-luc

HCC827 is among the most published human lung cancer lines in EGFR research, and its luciferase derivative extends it into imaging-guided orthotopic studies. Core attributes are summarized below.

Our Services

When the industry’s reference EGFR model is the substrate, execution must be equally canonical — and that is the posture Alfa Cytology takes with HCC827-luc. Stocks trace to authenticated CRL-2868 vials, passage history is capped, and every luciferase lot is released only after uniform in vitro glow output is demonstrated. Intrathoracic implantation follows written technique with immediate post-injection imaging verification, randomized arms are balanced by baseline photon flux, and optional erlotinib reference arms anchor cross-study comparability. From first scan to final thoracic histopathology, Alfa Cytology runs the HCC827 / HCC827-luc orthotopic program as a single accountable preclinical workflow.

Workflow of HCC827 / HCC827-luc Orthotopic Mouse Model Construction

The HCC827-luc orthotopic workflow is built for a tumor that grows quickly in a confined thoracic space: precision in delivery, discipline in imaging cadence, and rigor in randomization determine whether the efficacy signal resolves cleanly. The sequence below is the standard construction-to-analysis flow.

1. Authentication and reporter release: HCC827 / HCC827-luc stocks are expanded from authenticated master banks at capped passage, mycoplasma-tested, and released only after uniform firefly luciferase expression is confirmed by serial in vitro luminescence assay.
2. Inoculum preparation: Log-phase adherent cultures are released with trypsin/EDTA, washed, counted, and resuspended in sterile DPBS at about 2×10⁶ to 3×10⁶ cells in 100 µL per mouse.
3. Recipient preparation: Female BALB/c nude mice are acclimatized, body-weight stratified, anesthetized with isoflurane, and positioned with chest disinfection and thermal support.
4. Intrathoracic implantation: A fine needle is advanced at roughly 45 degrees alongside the sternum to shallow depth, and the suspension is delivered into the thoracic cavity or mediastinal region; immediate imaging confirms thoracic signal localization, verifying correct deposition.
5. Recovery and baseline imaging: Animals recover under monitoring, and baseline whole-body bioluminescence after intraperitoneal D-luciferin (150 mg/kg) documents engraftment and starting photon flux.
6. Serial imaging and randomized dosing: Thoracic photon flux is tracked on a fixed schedule alongside body weight and respiratory clinical signs; animals are randomized by matched baseline signals, and treatment begins — with optional erlotinib reference arms — according to the study plan.
7. Terminal workup and histopathology: At endpoint, thoracic tumors are excised and weighed, lungs and mediastinum are inspected and imaged ex vivo, dissemination is scored, and tissues undergo H&E plus EGFR-pathway marker immunohistochemistry to confirm adenocarcinoma histology and treatment effect.

Fig 2. HCC827 / HCC827-luc orthotopic mouse model construction workflow.

Case Study-HCC827 / HCC827-luc Orthotopic Mouse Model Development

Alfa Cytology has supported preclinical programs on the HCC827 orthotopic platform for sponsors advancing next-generation EGFR inhibitors, rational combinations, and resistance-overcoming strategies. In these engagements, serial thoracic bioluminescence resolved treatment-induced regression and relapse kinetics against matched baselines, erlotinib-class reference arms provided cross-study anchors, and terminal analyses combined tumor weights, ex vivo thoracic imaging, and EGFR-pathway immunohistochemistry. Where sponsors required resistance-context data, extended dosing designs captured emergent bypass signaling readouts. Program-specific parameters and outcomes are maintained as sponsor-confidential deliverables, and representative outlines can be shared on request.

Why Choose Alfa Cytology?

For the oncology field’s benchmark EGFR model, only benchmark-grade execution will do. Alfa Cytology’s HCC827-luc service pairs authenticated reagents, thoracic surgical discipline, and imaging rigor into one accountable workflow. Sponsors choosing it gain:

• Authenticated CRL-2868 / ACC 566 stocks at capped passage with verified luciferase output before study release.
• Intrathoracic implantation technique with immediate post-injection imaging verification of tumor deposition.
• Signal-matched randomization that balances arms against thoracic disease heterogeneity.
• Optional erlotinib-class reference arms aligned with the model’s canonical TKI sensitivity.
• Resistance-aware designs that can capture MET/AXL bypass readouts in extended-dosing studies.
• Terminal packages spanning tumor metrics, ex vivo thoracic imaging, and pathway-marker histopathology.
• A single accountable team reporting at every imaging timepoint from implantation to final analysis.

Contact Us

Ready to benchmark your EGFR program on the field’s canonical mutant model in a true thoracic setting? Contact us to discuss implantation, imaging cadence, and reference-arm design for the HCC827 / HCC827-luc orthotopic platform. Alternatively, reach out to Alfa Cytology for a customized proposal and quotation — our team will return a study design aligned with your mechanism and timeline.

For research use only. Not intended for any clinical use.